2018 Apr

Established GMP facility for SR-formulation in Osong (135, Uiryodanji-gil, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do)

2015 Jul

KOSDAQ listed

2015 Jan

SR-Exenatide for Diabetes Phase II study completed in Korea

2014 Dec

CRADA signed with National institute of Aging (NIA) for neurodegenerative drug development

2009Jan

Moved the Company’s Headquarters and its affiliated R&D institute (37-24 Yuseong-daero, 1628beon-gil, Yuseong-gu, Daejeon)

2003 Aug

Signed Licensing Agreement with Daewoong Pharmaceutical Co, Ltd. on the Technology Transfer and the Joint commercialization of 1 and 3 Months SR-Leuprolide injectable Formulations as Prostate Cancer Treatment Drug

2001 Sep

Certification of ISO 9001 for peptide manufacturing

2001 Aug

Certification as a Technology innovation SME (INNO-BIZ)

1998 Sep

Initiated producing of peptide materials as investigational drug materials

1998 Jun

Established the company affiliated R&D institute named as Peptron Biochemistry Research institute

1997 21 Nov

Establishment of Peptron, lnc.